ReviewThe Lancet. Oncology2013
Is cancer gene therapy an empty suit?
Review in The Lancet. Oncology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Acceptance of Cell and Gene Therapy Among Patients with Hematological Diseases in China: A Cross-Sectional Study.Patient preference and adherence · 2026Article
- Thylakoids for enhanced photodynamic therapy in hypoxic tumours.Science and technology of advanced materials · 2025Review
- Pseudotyped lentiviral vectors: Ready for translation into targeted cancer gene therapy?Genes & diseases · 2023Review
- Public Attitudes About the Use of Gene Therapy in Mainland China.JAMA network open · 2023Article
- Review
- Biocompatible Iron Oxide Nanoparticles for Targeted Cancer Gene Therapy: A Review.Nanomaterials (Basel, Switzerland) · 2022Review
- White Paper: Mimetics of Class 2 Tumor Suppressor Proteins as Novel Drug Candidates for Personalized Cancer Therapy.Cancers · 2022Article
- Review
- Advances in the treatment of intraocular malignancies: A literature review.Frontiers in medicine · 2022Review
- Improved safety of induced pluripotent stem cell-derived antigen-presenting cell-based cancer immunotherapy.Molecular therapy. Methods & clinical development · 2021Article
- Therapeutic activity of retroviral replicating vector-mediated prodrug activator gene therapy for pancreatic cancer.Cancer gene therapy · 2018Article
- MIS416 as a siRNA Delivery System with the Ability to Target Antigen-Presenting Cells.Nucleic acid therapeutics · 2018Article
- Dual-functional peptide with defective interfering genes effectively protects mice against avian and seasonal influenza.Nature communications · 2018Article
- Survivin-Based Treatment Strategies for Squamous Cell Carcinoma.International journal of molecular sciences · 2018Review
- Response to "An innovative mesothelioma treatment based on mir-16 mimic loaded EGFR targeted minicells (TargomiRs)".Translational lung cancer research · 2018Article
- Folic acid-decorated polyamidoamine dendrimer exhibits high tumor uptake and sustained highly localized retention in solid tumors: Its utility for local siRNA delivery.Acta biomaterialia · 2017Article
- Fail-Safe System against Potential Tumorigenicity after Transplantation of iPSC Derivatives.Stem cell reports · 2017Article
- Regulatory and Scientific Advancements in Gene Therapy: State-of-the-Art of Clinical Applications and of the Supporting European Regulatory Framework.Frontiers in medicine · 2017Review
- Initial Characterization of Integrase-Defective Lentiviral Vectors for Pancreatic Cancer Gene Therapy.Human gene therapy · 2016Article
- Synergistic tumor suppression by adenovirus-mediated ING4/PTEN double gene therapy for gastric cancer.Cancer gene therapy · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Gene therapy as a treatment for cancer is regarded as high in promise, but low in delivery, a deficiency that has become more obvious with ever-increasing reports of the successful correction of monogenic disorders by this approach. We review the commercial and scientific obstacles that have led to these delays and describe how they are progressively being overcome. Recent and striking successes and correspondingly increased commercial involvement suggest that gene transfer could finally become a powerful method for development of safe and effective cancer therapeutic drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.